Table 1: Baseline Characteristics.

CharacteristicEZE + Statin STAT2 Value
(Between-Group)

Age, years, mean ± SD60 ± 1054 ± 130.048
Women, (%)14 (41.2)9 (30.0)0.437
Weight, kg, mean ± SD 74.8 ± 13.40.310
 Overweight (Body Mass Index > 27 kg/m2), (%)9 (26.5)11 (36.7)0.380
Country of Ethnic Origin, (%)0.660
 India14 (41.2)10 (33.3)
 Pakistan5 (14.7)6 (20.0)
 Sri Lanka13 (38.2)10 (33.3)
 Other2 (5.9)4 (13.3)
Known Coronary Artery Disease, (%)16 (47.1)15 (50.0)0.814
Diabetes*, (%)22 (64.7)21 (70.0)0.653
Hypertension*, (%)20 (58.8)13 (43.3)0.216
Current smoker, (%)1 (2.9)3 (10.0)0.506
Metabolic Syndrome**, (%)9 (26.5)8 (26.7)>0.999
 Abdominal obesity21 (61.2)21 (70.0)
 Elevated triglycerides 9 (26.5)6 (20.0)
 Elevated fasting blood glucose 10 (29.4)10 (33.3)
 Low HDL cholesterol 19 (55.6)13 (43.3)
 Elevated blood pressure 130/85 mmHg2 (5.9)8 (26.7)
History of Statin Use, (%)
 Before study
  Atorvastatin22 (64.7)23 (76.7)
  Rosuvastatin6 (17.6)5 (16.7)
  Simvastatin3 (8.8)1 (3.3)
Statin therapy at Baseline
 Atorvastatin34 (100.0)30 (100.0)
  10 mg14 (41.2)13 (43.3)
  20 mg14 (41.2)8 (26.7)
  40 mg4 (11.8)7 (23.3)

*Treated by medication **Metabolic syndrome definition: 3 of these risk factors: abdominal obesity (waist circumference > 90 cm (men) or >80 cm (women)); elevated triglycerides 1.7 mmol/L; elevated fasting blood glucose level 6.2 mmol/L; low HDL-Cholesterol level (<1.0 mmol/L (men) and <1.3 mmol/L (women)) and elevated blood pressure > 130/85 mm Hg